If you are developing a skincare or cosmetics range without your own factory, you will quickly meet three labels: OEM, ODM and private label. Each suggests a different split of work between you and the manufacturer, and a different answer to the question that matters most later: whose product is this, exactly?
This guide uses the most common meanings of the terms, points out where usage varies, and turns the differences into practical questions. The examples are hypothetical and exist only to illustrate the trade-offs.
Why the terms cause confusion
None of the three terms is a legal category in UK cosmetics law. The GB rules are organised around roles such as the Responsible Person, not around business models (GOV.UK). Korea's Cosmetics Act distinguishes a cosmetic manufacturing business from a responsible cosmetic distribution business, but it does not define "OEM" or "ODM" either (Cosmetics Act).
In practice, the labels are commercial shorthand, and manufacturers use them differently. Some use "OEM" for any contract manufacturing. Others offer "ODM" services that are really a lightly adjusted stock formula. The safest approach is to treat the label as a starting point and set out in writing who does what.
OEM: made to your specification
In the classic original equipment manufacturer (OEM) arrangement, the brand supplies the formula and specification, often developed with an independent formulator, and the manufacturer produces it. The manufacturer contributes production capability, quality control and often sourcing, but the product concept and formula come from you.
The advantages are control and, usually, a clearer claim to the formula. The costs are responsibility and time. You, or the people you commission, must develop the formula, generate or commission stability and safety data, and answer technical questions the manufacturer would otherwise handle. OEM suits businesses with a clear product idea and access to formulation expertise.
ODM: developed and made by the manufacturer
An original design manufacturer (ODM) develops the product as well as making it. You describe what you want, and the ODM's research team proposes formulas, often starting from its existing library and then adjusting texture, fragrance, colour or actives to your brief.
This model is a large part of how Korea's beauty sector works. A 2026 Korea Herald report, drawing on Yonhap, described it as allowing brands to "focus on marketing, branding and distribution while outsourcing research and production to specialized manufacturers" (Korea Herald).
ODM can shorten development considerably and give smaller brands access to substantial research capability. The central trade-off is ownership. Because the formula grew from the manufacturer's know-how, it often remains the manufacturer's property unless the contract says otherwise. That affects whether you can move production elsewhere and whether a similar formula might be sold to another brand.
Private label: an existing product, your label
Private label, or "own label" in UK retail language, usually means choosing a finished product from a manufacturer's range and selling it under your brand, with limited or no change to the formula. Customisation typically stops at packaging, printing and perhaps fragrance.
It is the fastest route to market and requires the least development. It also offers the least differentiation, because the same formula may appear under several brand names. For a business testing demand, or adding supporting products around a core range, that can be an acceptable trade.
The three models side by side
| OEM | ODM | Private label | |
|---|---|---|---|
| Formula developed by | Brand or its formulator | Manufacturer, to the brand's brief | Manufacturer (existing product) |
| Formula usually owned by | Brand, if the contract says so | Often the manufacturer, unless agreed otherwise | Manufacturer |
| Customisation | High | Moderate to high | Low |
| Development time | Longest | Shorter | Shortest |
| Brand's technical workload | Highest | Moderate | Lowest |
| Main risk | Development cost and delay | Dependence on one manufacturer | Little differentiation |
Minimum order quantities (MOQs) do not follow a neat pattern across the models. They depend on batch sizes, raw materials and, very often, packaging components. A private-label product in stock packaging can have a low minimum, while a custom bottle can raise the minimum for any model.
Three hypothetical examples
The businesses below are invented to illustrate the models. They do not describe any real company, product or SYH Group project.
Example A: an OEM serum
A UK clinic group commissions an independent cosmetic scientist to develop a serum. It owns the resulting formula under its agreement with the scientist, then asks a manufacturer to produce it to that specification. The group carries more development cost, but can later move production if it needs to, provided the manufacturing contract does not say otherwise.
Example B: an ODM moisturiser
A start-up brand briefs an ODM on a lightweight gel moisturiser. The ODM adapts a formula from its library. The brand gets to market quickly, but learns late that it has no rights to the formula and that a close relative is sold elsewhere. It could have negotiated exclusivity for its market, or a transfer of ownership, before development began.
Example C: a private-label cleanser
A salon adds a cleanser to complement its treatments. It selects a stock formula, chooses a stock tube and prints its own design. It accepts limited differentiation in exchange for speed and a modest first order.
Formula ownership and confidentiality
Formulas are usually protected as confidential information rather than by registration. The UK Intellectual Property Office explains that the law of confidentiality protects trade secrets, and that to keep them protected you must establish that the information is confidential and ensure that anyone you tell signs a non-disclosure agreement (IPO).
The same guidance makes a point that applies directly to commissioned development: if you commission others to create work for your business, agree who will own it before the work is created (IPO). In our view the contract should cover:
- who owns the final formula, and any improvements made during development;
- whether the brand receives exclusivity, for which markets and for how long;
- whether the full quantitative formula can be shared with the brand's safety assessor;
- what happens to the formula and data if the relationship ends.
Your brand name and packaging design are separate assets. The IPO notes that a registered trade mark can protect a brand name or logo, and that a registered design protects the appearance of a product, which can include packaging (IPO). If you manufacture abroad, consider protection there as well. The IPO's guidance on South Korea explains the role of the Korean Intellectual Property Office (IPO, South Korea).
Packaging and customisation
Packaging choices often decide cost, timing and minimums more than the formula does. Stock containers are faster and usually carry lower minimums. Custom moulds, special finishes and printed components add time and supplier minimums of their own. Whatever you choose, the formula must be compatible with the container. That is a technical question, covered in our article on packaging and stability.
Agree who sources each component, who checks its quality on arrival, and who pays for components left over when a product changes or is discontinued.
Responsibilities to settle in writing
In Great Britain, the Responsible Person may be the manufacturer, the importer, a distributor that sells the product under its own brand, or a person appointed by the manufacturer or importer, and they must have a UK address (GOV.UK). For many UK brands working with an overseas manufacturer, that role sits with the brand. It carries duties that depend on information from the manufacturer.
The Product Information File must include, among other things, a description of the product, the safety report, the manufacturing method and good manufacturing practice, and proof of the effect claimed where this is justified by the nature or effect of the product (OPSS guidance). Before signing, agree:
- which party supplies each input to the safety assessment and the Product Information File;
- who holds evidence for each product claim;
- how batches are released and what certificate accompanies each delivery;
- how formula changes and raw material substitutions will be notified;
- how complaints, adverse reactions and any recall will be handled between you.
None of this requires choosing one model for ever. Many brands mix them, perhaps OEM for a signature product and private label for supporting items. What matters is knowing, product by product, what you own, what you depend on and who answers for it.
